# Bio-Rad Laboratories, Inc.Class A (BIO) — Stock CV

Bio-Rad Laboratories, Inc.Class A is a $9.79B technology company. Revenue grew 1.4% over the last year, it keeps 9¢ of every dollar of sales as profit, and it holds more cash than debt. It trades at 44.3× earnings — in the most expensive third of its own history.

> Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories.

## Identity

- **Ticker**: BIO
- **Sector**: Technology
- **Industry**: Laboratory Analytical Instruments
- **Headquarters**: HERCULES, CA
- **Employees**: 7 450
- **Website**: https://www.bio-rad.com
- **Market cap**: $9.79B
- **Last price**: $366.16
- **Financial profile**: Strong

## Vitals (TTM)

- **Revenue**: $2.59B
- **Net income**: $222M
- **Free cash flow**: $353M
- **Net cash**: $339M
- **P/E**: 44.3
- **Revenue growth (YoY)**: 1.4%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 37 |
| Growth | 20 |
| Profitability | 35 |
| Health | 78 |
| Quality | 60 |
| Moat | 38 |

## Qualifications (beginner checklist) — 9 of 10 passed

- [x] Revenue growing — +1.4% YoY
- [x] Profitable — $222M TTM
- [ ] Profit growing — -26.1% YoY
- [x] Generates cash — $353M TTM
- [x] Debt under control — more cash than debt
- [x] Established company — $9.79B market cap
- [x] Not printing shares — -9.5% shares over ~5y
- [x] Proven track record — 7/10 profitable years
- [x] Financially stable — Altman Z 3.4 — safe
- [x] Valuation not extreme — P/E 44.3

## Experience (career milestones)

- **FY2021** — Best year on record: $4.25B net income
- **FY2018** — Revenue crossed $1B: $2.29B for the year
- **FY2018** — Positive free cash flow every year since: 8-year streak
- **2017** — Bio-Rad acquired RainDance Technologies, a droplet-based PCR systems manufacturer
- **FY2016** — First recorded profitable year: $28.1M net income
- **2013** — Bio-Rad purchased AbD Serotec, a division of MorphoSys AG
- **2011** — Bio-Rad acquired a new technology, droplet digital PCR
- **2008** — Bio-Rad were notable for being the opening bell ringers at the New York Stock Exchange on 24 October, a…
- **1989** — Bio-Rad purchased the British instrument-making firm, Vickers (1828 - 1999), apart from their defense products
- **1976** — Bio-Rad acquired Environmental Chemical Specialties (ECS), a producer of human control serum
- **1965** — Bioradiations began as a print magazine that was launched in 1965 and was printed until 2011 and replaced with the…

## Strengths

- High gross margin (51.9%)
- Net cash position after subtracting debt from cash
- Altman Z-Score 3.41 — low bankruptcy-risk zone

## Watch-outs

- Thin interest coverage (0.1×)
- Loss-making in 3 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $2.92B | $4.25B | $536M |
| FY2022 | $2.80B | -$3.63B | $81.6M |
| FY2023 | $2.67B | -$637M | $218M |
| FY2024 | $2.57B | -$1.84B | $290M |
| FY2025 | $2.58B | $760M | $375M |

---

Source: https://stockcv.com/BIO — derived from company filings; may be delayed or incomplete. Information, not investment advice.